Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502456 · ClinicalTrials.gov registry record · NA
Clareon TruPlus Study
A NA study, sponsored by Alcon Research.
- Recruiting
- Registry status
- NA
- Development phase
- 122
- Enrollment target
NCT07502456: Recruiting NA study, sponsored by Alcon Research.
NCT07502456 is a NA study that is actively recruiting participants, run by Alcon Research. The registered enrollment target is 122 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07502456, a NA study, is actively recruiting participants, sponsored by Alcon Research.
- RECRUITING
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.
Primary Outcome
Visual acuity (VA) will be assessed binocularly (both eyes together) with correction in place under photopic (well-lit) conditions at a distance of 4 meters. BCDVA will be measured using letter charts and recorded in logarithm of the Minimum Angle of Resolution (logMAR). The LogMAR VA scale ranges from -0.30 (20/10 Snellen) to 1.00 (20/200 Snellen). A LogMAR value of 0 equates to 20/20 Snellen VA (normal distance eyesight), with negative LogMAR values representing better than 20/20 VA. Subjects
Interventions
- PROCEDURE Phacoemulsification
- DEVICE Clareon TruPlus Monofocal Non-Toric IOL
- DEVICE Clareon TruPlus Monofocal Toric IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2026-05-26 |
| Est. Completion | 2028-06 |
| Phase | NA |
What NCT07502456 shows while recruiting
NCT07502456 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Phacoemulsification is the first listed.
NCT07502456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07502456 about?
NCT07502456 is a clinical study titled "Clareon TruPlus Study". The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are inten...
What is the current status of trial NCT07502456?
This trial is currently recruiting. It is a NA study. The enrollment target is 122 participants. The study started on 2026-05-26. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07502456?
The interventions under investigation include: Phacoemulsification (PROCEDURE), Clareon TruPlus Monofocal Non-Toric IOL (DEVICE), Clareon TruPlus Monofocal Toric IOL (DEVICE).
Who is sponsoring clinical trial NCT07502456?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07502456's enrollment target sits among peer trials
122 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI